NCT05959447

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1, 2-part, open-label, fixed-sequence study evaluating potential drug-drug interactions between gemfibrozil (part 1) or dabigatran etexilate (part 2) and camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

Conditions

• Cough
• Healthy

Interventions

Type	Name	Description
DRUG	Camlipixant	Camlipixant will be administered
DRUG	Dabigatran etexilate	Dabigatran etexilate will be administered
DRUG	Gemfibrozil	Gemfibrozil will be administered.

Timeline

• Start date: 2023-07-26
• Primary completion: 2023-10-13
• Completion: 2023-10-13
• First posted: 2023-07-25
• Last updated: 2025-03-26
• Results posted: 2025-03-26

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study